Company Filing History:
1 out of 52 
1 out of 47 Years Active: 1998-2004
Title: Michelle Davenport: Innovator in Amylin Release Inhibition
Introduction
Michelle Davenport is a notable inventor based in Buckingham, GB. She has made significant contributions to the field of biochemistry, particularly in the area of amylin release inhibition. With a total of 2 patents, her work has the potential to impact treatments for conditions related to hyperamylinemia.
Latest Patents
Davenport's latest patents focus on a method for determining the ability of a compound to bind to the somatostatin type-5 receptor (SSTR-5) and inhibit amylin release. The method involves obtaining a preparation that contains SSTR-5, incubating it with a compound and a SSTR-5 ligand, and determining the compound's ability to compete for binding. If the compound binds to SSTR-5, pancreatic cells are obtained, and the compound is incubated with an amylin release stimulator to assess its ability to inhibit amylin release. This innovative approach also includes a method for treating hyperamylinemia using a ligand selective for SSTR-5.
Career Highlights
Throughout her career, Michelle has worked with various organizations, including Biomeasure Incorporated and Société de Conseils de Recherches et d'Applications Scientifiques SAS. Her experience in these companies has contributed to her expertise in the field of biochemistry and patent development.
Collaborations
Some of her notable coworkers include Simon Jon Dunmore and Michael Anthony Cawthorne. Their collaboration has likely enriched the research and development processes in which Davenport has been involved.
Conclusion
Michelle Davenport's innovative work in amylin release inhibition showcases her dedication to advancing medical science. Her patents and collaborations reflect her significant contributions to the field, paving the way for potential new treatments.